Biotechs starting to wake up

Last week, we saw some exciting movement in the biotech sector.  Some rather dormant stocks began to awaken, and may be getting ready for bigger runs. 

Propanc Health Group (PPCH) had a huge week climbing back above a penny per share on some major volume.  Some of this may be due to the exposure they received presenting at the LD Microcap Conference last week.

This kind of reaction after the presentation is a great sign for the company.  If you’d like to see a presentation on PPCH, the company also presented at a Virtual Investor Conference.  Propanc’s presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the “virtual trade booth” for the next three weeks.  It is all available at this link:

To view the new Propanc video “Mechanism of Action” on anti-cancer product candidate, PRP, please click on the following link:

It’s not a big surprise to see Propanc moving, the only surprise is that it wasn’t moving prior based on some of the company’s recent activity.  PPCH recentlyfiled applications for Orphan Medicinal Product Designation (OMPD) to the European Medicines Agency (EMA) for PRP, a solution for intravenous administration of pancreatic proenzymes trypsinogen and chymotrypsinogen. The proposed orphan drug indication for PRP is for the treatment of ovarian and pancreatic cancer, responsible for 338,000 cancer diagnoses and 331,000 deaths worldwide in 2012, and a major unmet medical issue.

PPCH also completed a 28 day toxicokinetic study to support determination of a safe starting dose in patients as the Company progresses towards clinical trials in 2017 for its lead product, PRP.

They’ve also executed a contract manufacturing agreement with AmatsiQBiologicals, based in Gent, Belgium . The agreement covers the development and GMP (Good Manufacturing Practice) production of certain enzymes for development purposes, including but not limited to first-in-man studies for the Company’s lead product, PRP.

These are all major milestones which are setting up for even bigger milestones in the near future. 

A few other movers from last week include:

AC Immune SA (ACIU)  a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that its partner Genentech, member of Roche group, presented important data to support the unique binding and increased dosing of its Alzheimer’s therapy on crenezumab, an anti-Abeta antibody.  They were from a Phase 1b safety study and an exposure-response model to evaluate the best dose of crenezumab for the treatment of people with Alzheimer’s disease. The model predicts, relative to the Phase 2 trials, an improved outcome of the CREAD Phase 3 clinical trial in patients with prodromal-to-mild Alzheimer by using the higher dose of 60mg/kg of crenezumab.

Emergent BioSolutions, Inc. (EBS) was up 19.5% Friday after announcing a new contract with the Centers for Disease Control and Prevention (CDC) and a separate deal with the Biomedical Advanced Research and Development Authority (BARDA), both to supply its anthrax vaccine BioThrax to the Strategic National Stockpile. So what Emergent BioSolutions previously disclosed that the CDC had picked the biotech as its sole source for anthrax vaccine — not surprisingly since Emergent is the only company with an anthrax vaccine licensed by the Food and Drug Administration — but the details on pricing and delivery were still to be worked out.

Sangamo BioSciences, Inc. (SGMO) a leader in therapeutic genome editing, presented preclinical and manufacturing data that support SB-525, its gene therapy program for hemophilia A, at the 58th Annual Meeting of the American Society of Hematology (ASH) being held in San Diego, CA.

Opexa Therapeutics, Inc. (OPXA) had a huge day Friday without any major news to speak of, this will be worth monitoring.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Click Here.

Media Contact
Company Name: Microcap Speculators
Contact Person: Media Manager
Phone: 1-702-720-6310
Country: United States